Hematologic Malignancies

Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), additional therapies may be able to perform equally well in select patients, said Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.
At the National Comprehensive Cancer Network 2020 Virtual Congress: Hematalogic Malignancies, Shaji Kumar, MD, Consultant and Professor of Medicine, Division of Hematology, Mayo Clinic Cancer Center, Rochester, MN, discussed the “bonanza of treatment regimens for multiple myeloma.”
The approaches to the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma are evolving, including the sequencing of therapy and a possibly expanded role for minimal residual disease (MRD) status, said William G. Wierda, MD, PhD, Section Chief, Chronic Lymphocytic Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.
Although smoldering myeloma is acknowledged as a clinical entity, debate continues about whether to treat, when to treat, and how to treat this condition, said Natalie S. Callander, MD, Leader, Myeloma/Lymphoma Disease-Oriented Team, University of Wisconsin Carbone Cancer Center, Madison, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.

Results 1 - 4 of 4